Tonix Pharmaceuticals Presents Lyme Disease and Smallpox Vaccine Data at World Vaccine Congress — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals will present Phase 1 data on TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, at the World Vaccine Congress Washington 2026 on March 30.
The company will also share animal and in vitro studies on TNX-801, a horsepox-based vaccine candidate for smallpox and mpox prevention, on April 1.
TNX-4800 demonstrated a mean half-life of 62-69 days and was generally safe and well-tolerated in the Phase 1 study.
Tonix expects to initiate a field study for TNX-4800 in the first half of 2027, pending FDA clearances.

The big picture

Tonix Pharmaceuticals is positioning itself at the forefront of infectious disease prevention with its innovative vaccine candidates. The company's focus on Lyme disease and smallpox/mpox vaccines aligns with growing public health needs, particularly as vector-borne diseases expand due to climate change. Tonix's ability to advance these programs through clinical trials and regulatory hurdles will be critical for its long-term success in the competitive biotechnology sector.

What we're watching

Regulatory Pathway: Whether TNX-4800 can secure FDA clearance for its field study in 2027, given the historical challenges faced by Lyme disease vaccines.
Market Opportunity: The pace at which Tonix can commercialize TNX-4800, considering the rising incidence of Lyme disease in the U.S.
Pipeline Progress: How the data from TNX-801 will position Tonix in the smallpox and mpox vaccine market, especially with the ongoing global health concerns around mpox.